Skip Ribbon Commands
Skip to main content

The AACR Call to Action

In this section you will learn:


​The AACR respectfully urges Congress and the administration to prioritize the growth of the NIH, NCI, and FDA budgets, which will require working together in a bipartisan fashion to reach a comprehensive budget agreement that eliminates sequestration and raises current caps on federal spending.

Following more than a decade of budget stagnation and outright funding cuts, thus far in 2015, the administration and a bipartisan majority of members of Congress have demonstrated a strong commitment to increasing the budgets for the NIH, NCI, and FDA.

During this time of unprecedented promise in biomedical research, robust, sustained, and predictable investments in the NIH and NCI are urgently needed. This is a sentiment shared by the majority of American voters, as a 2015 national survey conducted on behalf of the AACR by Hart Research Associates and Public Opinion Strategies found that three out of every four voters favor increasing federal funding of cancer research.

Therefore, the AACR respectfully urges Congress and the administration to:

Implement a strategy for robust, sustained, and predictable growth for the NIH and NCI by providing annual budget increases of at least 7 percent. This level of funding would represent strong growth in excess of the biomedical inflation rate, resulting in fiscal year (FY) 2020 funding levels for the NIH and NCI of $42.5 billion and $7 billion, respectively.

Increase the FDA budget in FY 2016 by $200 million above its FY 2015 level (a 7 percent increase from $2.6 billion to $2.8 billion) and ensure that the agency receives comparable annual percentage increases thereafter.

Achieving these goals will require Congress to work in a bipartisan fashion to enact a broad-based budget deal that raises the discretionary funding caps for FY 2016 and beyond. This would allow our nation’s policymakers to invest in priority areas, such as biomedical research, cancer research, and regulatory science, which will speed innovation and accelerate the pace of development of products that are safe, effective, and ultimately advance public health.

By committing to provide the NIH, NCI, and FDA with annual funding increases that are robust, sustained, and predictable, we will transform cancer care, spur innovation and economic growth, maintain our position as the global leader in science, biomedical and cancer research, and, most importantly, bring hope to patients and their loved ones.